Opportunity Information: Apply for HT9425 23 PCRP EIRA
The FY23 DoD Prostate Cancer Research Program (PCRP) Early Investigator Research Award is designed to help postdoctoral researchers launch an independent career trajectory in prostate cancer research while working under the close guidance of one or more established mentors. The central idea is to give an early-career scientist the chance to lead a prostate cancer-focused project from concept through execution, build a strong foundation of skills and credentials, and mature into a competitive, independent investigator. Even though the work is mentored, the postdoctoral applicant is treated as the Principal Investigator (PI) for the application, and the expectation is that the PI personally authors the full application package, using the mentor team for direction and strategic support rather than as the primary drivers of the proposal.
Eligibility and fit are tightly aligned to “early investigator” status. The PI must be a postdoctoral investigator with no more than 3 years of postdoctoral research experience as of March 31, 2024, with clinical residency or clinical fellowship time explicitly excluded from that calculation. Prior prostate cancer research experience is not required, but the PI must clearly demonstrate strong potential and a genuine commitment to building a career at the forefront of prostate cancer research. The program also signals a strong interest in developing talent in health disparities research: applicants who show a commitment to prostate cancer health equity and disparity-focused work are strongly encouraged, which effectively makes disparity-related proposals and career plans especially responsive to the program’s direction.
Mentorship is a required backbone of the award. Each application must include at least one mentor with demonstrated prostate cancer research and mentoring experience, supported by evidence such as active funding, recent peer-reviewed publications, and a track record of successfully guiding trainees. A primary mentor may be a junior faculty member, but in that case the program encourages adding a secondary mentor with a deeper or more established record in prostate cancer research and mentorship to strengthen both scientific oversight and career development support. If the research is centered on health disparities, the expectation is that the mentor team includes at least one person with direct experience in prostate cancer health disparity research. Beyond credentials, mentors are expected to show real commitment to moving the PI toward independence, not simply supervising a project.
On the science side, the proposed research must address one or more of the FY23 PCRP Overarching Challenges, and projects that directly advance health equity and reduce disparities in prostate cancer are particularly encouraged. Reviewers will be looking for a clear scientific rationale, thoughtful experimental design, and methods that show the applicant has deeply analyzed the research problem. Feasibility matters: the proposal should lay out a realistic plan for accomplishing the aims within the award period, explain how key technical or logistical hurdles will be handled, and clearly identify the resources required. Preliminary data can be included but is not mandatory; if provided, it should come from the PI, the mentor(s), or collaborators on the team. Research involving human subjects, human data, and human anatomical substances is allowed, but clinical trials are explicitly not allowed under this mechanism.
A major distinguishing feature of this opportunity is the required Researcher Development Plan. The PI must present an individualized plan that is clearly prostate cancer-focused and maps out how they will gain the skills, expertise, and professional development needed to complete the project and transition toward independence. The plan should describe the mentoring environment, training activities, and how the institution and collaborators will support the PI’s growth. If the home institution lacks certain resources or mentorship depth, the program allows those gaps to be addressed through collaborations, including use of resources at other institutions. When a collaborating institution is essential for key resources, the PI is strongly encouraged to name a co-mentor at that partner site, reinforcing accountability and day-to-day access to expertise.
The announcement also emphasizes research rigor, reproducibility, and translational relevance. Applicants are encouraged, where appropriate, to include cell line authentication plans, strong statistical rigor for animal studies, and experiments that help demonstrate clinical relevance and potential translatability. The program is receptive to modern, data-rich approaches as well, encouraging studies that leverage large patient datasets with long-term health records, biospecimen repositories, and existing research resources, especially when paired with state-of-the-art genomic/proteomic analyses, bioinformatics, or mathematical modeling. Because feasibility and access can make or break these projects, applicants are strongly encouraged to include letters of support documenting access to critical datasets, specimens, cores, or other enabling resources.
From an award administration standpoint, funding is issued as an assistance agreement, meaning it is intended to support a public purpose rather than procure goods or services for the government’s direct use. The award may be structured either as a grant or as a cooperative agreement, depending on the anticipated level of DoD involvement during the project. If no substantial involvement is expected, it will generally be a grant; if substantial involvement is anticipated (for example, collaboration or participation by the funding agency in aspects of the research), it may be issued as a cooperative agreement, with the nature of that involvement specified during negotiation.
Programmatically, the DoD highlights broader priorities that applicants may align with. As part of the congressionally mandated Metastatic Cancer Task Force efforts, applicants are encouraged to review the Task Force recommendations and propose research ideas that fit those recommendations as long as they also fit the PCRP priorities and the limitations of this specific award (including the prohibition on clinical trials). The program also strongly encourages collaborations between military or Veteran institutions and non-military institutions, emphasizing the value of combining infrastructure, expertise, and access to unique clinical populations to generate findings relevant to Warfighters, military families, Veterans, and the broader public.
In terms of funding scale and competitiveness, the anticipated direct cost budget for the entire period of performance should not exceed $300,000. The program expected to allocate about $7.2 million total to make roughly 15 awards, with the standard caveat that final funding depends on federal funds availability, application volume, and the outcome of scientific and programmatic review. Awards were expected to be made no later than September 30, 2024, and the FY23 funds associated with these awards are expected to remain available for use until they expire on September 30, 2029, which matters for the overall federal funding lifecycle and closeout windows.
Finally, applicants need to plan for compliance and regulatory timelines if their work involves humans or animals. Any DoD-funded work involving human data, human specimens, human subjects, or cadavers must undergo review by the USAMRDC Office of Human and Animal Research Oversight (OHARO), specifically the Office of Human Research Oversight (OHRO), in addition to local IRB or ethics review. Local IRB approval is not required at application submission, but it is required before OHRO review can occur, and applicants should expect up to about 3 months for OHRO review after all complete documents are submitted. For multi-site, non-exempt human subjects research in the US, a single IRB plan is required under 45 CFR 46.114(b), and the application or negotiations must identify how reliance arrangements will be handled and which institution will serve as the central IRB point of contact. For animal research, projects must also be reviewed by ACURO in addition to the local IACUC, with an estimated 3 to 4 months for ACURO review. Across both human and animal work, the program stresses rigorous study design and transparent reporting, referencing widely used standards like Landis et al. for preclinical rigor and the ARRIVE 2.0 guidelines for in vivo animal research reporting expectations.Apply for HT9425 23 PCRP EIRA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Early Investigator Research Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Apr 03, 2023.
- Applicants must submit their applications by Aug 24, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 15 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FY23 DoD Prostate Cancer Research Program (PCRP) Early Investigator Research Award - FAQs
What is the FY23 DoD PCRP Early Investigator Research Award?
This award is designed to help postdoctoral researchers launch an independent career trajectory in prostate cancer research while working under close guidance from one or more established mentors. The intent is for the postdoctoral applicant to lead a prostate cancer-focused project from concept through execution, while building skills, credentials, and a clear path toward becoming a competitive, independent investigator.
Who is the intended applicant for this opportunity?
The intended applicant is an early-career postdoctoral investigator who is ready to take scientific ownership of a prostate cancer research project while being supported by a mentor team. Although the work is mentored, the postdoctoral applicant is treated as the Principal Investigator (PI) for the application.
Is the postdoctoral applicant considered the Principal Investigator (PI)?
Yes. The postdoctoral applicant is treated as the PI for the application. The program expects the PI to personally author the full application package, using the mentor team for direction and strategic support rather than relying on mentors to drive the proposal.
How much postdoctoral experience is allowed to be eligible?
The PI must be a postdoctoral investigator with no more than 3 years of postdoctoral research experience as of March 31, 2024.
Does clinical residency or clinical fellowship time count toward the 3-year postdoctoral experience limit?
No. Clinical residency or clinical fellowship time is explicitly excluded from the calculation of postdoctoral research experience for eligibility.
Do I need prior prostate cancer research experience to apply?
No. Prior prostate cancer research experience is not required. However, the PI must clearly demonstrate strong potential and a genuine commitment to building a career at the forefront of prostate cancer research.
Are health disparities and health equity projects encouraged?
Yes. The program signals a strong interest in developing talent in health disparities research. Applicants who demonstrate a commitment to prostate cancer health equity and disparity-focused work are strongly encouraged, making such proposals and career plans especially responsive to the program direction.
Is mentorship required for this award?
Yes. Mentorship is a required backbone of the award. Each application must include at least one mentor with demonstrated prostate cancer research and mentoring experience.
What qualifies someone to serve as a mentor on this award?
Mentors are expected to demonstrate prostate cancer research and mentoring experience, supported by evidence such as active funding, recent peer-reviewed publications, and a track record of successfully guiding trainees.
Can the primary mentor be a junior faculty member?
Yes. A primary mentor may be a junior faculty member. If so, the program encourages adding a secondary mentor with a deeper or more established record in prostate cancer research and mentorship to strengthen scientific oversight and career development support.
If my project focuses on prostate cancer health disparities, are there mentor expectations specific to that area?
Yes. If the research is centered on health disparities, the mentor team is expected to include at least one person with direct experience in prostate cancer health disparity research.
What is the expectation of mentors beyond providing supervision?
Mentors are expected to show real commitment to moving the PI toward independence, not simply supervising a project. The mentorship should support both scientific development and career progression.
What must the proposed research address?
The proposed research must address one or more of the FY23 PCRP Overarching Challenges.
Are projects that reduce prostate cancer disparities viewed favorably?
Yes. Projects that directly advance health equity and reduce disparities in prostate cancer are particularly encouraged.
What will reviewers look for in the scientific proposal?
Reviewers will look for a clear scientific rationale, thoughtful experimental design, and methods showing the applicant has deeply analyzed the research problem. Feasibility is also emphasized, including a realistic plan to accomplish the aims within the award period and a clear explanation of how technical or logistical hurdles will be handled.
Is preliminary data required?
No. Preliminary data can be included but is not mandatory. If provided, it should come from the PI, the mentor(s), or collaborators on the team.
Are studies using human subjects, human data, or human specimens allowed?
Yes. Research involving human subjects, human data, and human anatomical substances is allowed under this mechanism.
Are clinical trials allowed under this award?
No. Clinical trials are explicitly not allowed under this mechanism.
What is the Researcher Development Plan, and is it required?
The Researcher Development Plan is a required, individualized plan that must be clearly prostate cancer-focused. It should map out how the PI will gain the skills, expertise, and professional development needed to complete the project and transition toward independence. The plan should describe the mentoring environment, training activities, and how the institution and collaborators will support the PI's growth.
Can collaborations be used to fill gaps in institutional resources or mentorship?
Yes. If the home institution lacks certain resources or mentorship depth, the program allows those gaps to be addressed through collaborations, including the use of resources at other institutions.
When is it recommended to name a co-mentor at a collaborating institution?
When a collaborating institution is essential for key resources, the PI is strongly encouraged to name a co-mentor at that partner site to reinforce accountability and ensure day-to-day access to expertise.
What kinds of research practices does the program emphasize regarding rigor and reproducibility?
The announcement emphasizes research rigor, reproducibility, and translational relevance. Applicants are encouraged, where appropriate, to include cell line authentication plans, strong statistical rigor for animal studies, and experiments that demonstrate clinical relevance and potential translatability.
Does the program encourage data-rich or computational approaches?
Yes. The program encourages studies that leverage large patient datasets with long-term health records, biospecimen repositories, and existing research resources, especially when paired with genomic/proteomic analyses, bioinformatics, or mathematical modeling.
Should applicants include letters of support for access to datasets, specimens, or shared resources?
Yes. Applicants are strongly encouraged to include letters of support documenting access to critical datasets, specimens, cores, or other enabling resources, since feasibility and access can strongly affect project success.
What type of federal funding instrument is used for this award?
Funding is issued as an assistance agreement, intended to support a public purpose rather than procure goods or services for the government's direct use.
Will awards be grants or cooperative agreements?
The award may be structured either as a grant or as a cooperative agreement, depending on the anticipated level of DoD involvement during the project. If no substantial involvement is expected, it will generally be a grant. If substantial involvement is anticipated, it may be issued as a cooperative agreement, with the nature of that involvement specified during negotiation.
What is the maximum anticipated direct cost budget for this award?
The anticipated direct cost budget for the entire period of performance should not exceed $300,000.
How many awards and how much total funding were expected?
The program expected to allocate about $7.2 million total to make roughly 15 awards, with final funding dependent on federal funds availability, application volume, and the outcome of scientific and programmatic review.
When were awards expected to be made?
Awards were expected to be made no later than September 30, 2024.
How long are the FY23 funds expected to remain available for use?
The FY23 funds associated with these awards are expected to remain available for use until they expire on September 30, 2029, which affects the overall federal funding lifecycle and closeout windows.
Are collaborations with military or Veteran institutions encouraged?
Yes. The program strongly encourages collaborations between military or Veteran institutions and non-military institutions to combine infrastructure, expertise, and access to unique clinical populations, with the goal of generating findings relevant to Warfighters, military families, Veterans, and the broader public.
How do the Metastatic Cancer Task Force recommendations relate to this opportunity?
As part of the congressionally mandated Metastatic Cancer Task Force efforts, applicants are encouraged to review Task Force recommendations and propose research ideas that fit those recommendations, as long as they also fit PCRP priorities and the limitations of this award (including the prohibition on clinical trials).
Do I need local IRB approval at the time of application submission?
No. Local IRB (or equivalent ethics) approval is not required at application submission. However, local IRB approval is required before DoD OHRO review can occur.
What additional human research oversight is required for DoD-funded studies?
Any DoD-funded work involving human data, human specimens, human subjects, or cadavers must undergo review by the USAMRDC Office of Human and Animal Research Oversight (OHARO), specifically the Office of Human Research Oversight (OHRO), in addition to local IRB or ethics review.
How long should applicants expect OHRO review to take?
Applicants should expect up to about 3 months for OHRO review after all complete documents are submitted.
Is a single IRB plan required for multi-site human subjects research?
Yes. For multi-site, non-exempt human subjects research in the United States, a single IRB plan is required under 45 CFR 46.114(b). The application or negotiations must identify how reliance arrangements will be handled and which institution will serve as the central IRB point of contact.
What oversight applies to animal research under this award?
Animal research must be reviewed by ACURO in addition to the local IACUC.
How long should applicants expect ACURO review to take?
Applicants should expect approximately 3 to 4 months for ACURO review.
What reporting or study design standards are referenced for rigor in preclinical and animal work?
The program references widely used standards such as Landis et al. for preclinical rigor and the ARRIVE 2.0 guidelines for in vivo animal research reporting expectations, alongside an emphasis on rigorous study design and transparent reporting.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Fiscal Year 2023 Community Assistance Program-State Support Services Element (CAP-SSSE) Region 2
Previous opportunity: Georgia NRCS Technical Outreach and Education for Fiscal Year 2023
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HT9425 23 PCRP EIRA
Applicants also applied for:
Applicants who have applied for this opportunity (HT9425 23 PCRP EIRA) also looked into and applied for these:
| Funding Opportunity |
|---|
| Rehabilitation Engineering Research Centers (RERC) Program: RERC on Universal Access to Information and Communication Technology Apply for HHS 2023 ACL NIDILRR REGE 0097 Funding Number: HHS 2023 ACL NIDILRR REGE 0097 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $925,000 |
| DoD Peer Reviewed Cancer, Career Development Award Apply for HT9425 23 PRCRP CDA Funding Number: HT9425 23 PRCRP CDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Advancing Cancer Care through Clinical Trials Award Apply for HT9425 23 PRCRP ACCCT Funding Number: HT9425 23 PRCRP ACCCT Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Impact Award Apply for HT9425 23 PRCRP IPA Funding Number: HT9425 23 PRCRP IPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Idea Award Apply for HT9425 23 PRCRP IA Funding Number: HT9425 23 PRCRP IA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Translational Team Science Award Apply for HT9425 23 PRCRP TTSA Funding Number: HT9425 23 PRCRP TTSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Patient Well-Being and Survivorship Award Apply for HT9425 23 PRCRP PWSA Funding Number: HT9425 23 PRCRP PWSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOE Traineeship in Accelerator Science & Technology Apply for DE FOA 0003025 Funding Number: DE FOA 0003025 Agency: Department of Energy - Office of Science, Office of Science Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Center of Excellence on New Mobility and Automated Vehicles Apply for 693JJ323NF00008 Funding Number: 693JJ323NF00008 Agency: Department of Transportation, DOT Federal Highway Administration Category: Science and Technology and other Research and Development Funding Amount: $7,500,000 |
| DoD Tick-Borne Research Program Idea Development Award Apply for HT9425 23 TBDRP IDA Funding Number: HT9425 23 TBDRP IDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Rehabilitation Research and Training Center (RRTC) on Disability Statistics and Demographics Apply for HHS 2023 ACL NIDILRR RTGE 0028 Funding Number: HHS 2023 ACL NIDILRR RTGE 0028 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $875,000 |
| DoD Tick-Borne Disease Research Program Therapeutic/Diagnostic Research Award Apply for HT9425 23 TBDRP TDRA Funding Number: HT9425 23 TBDRP TDRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Interfacial Engineering Apply for PD 23 1417 Funding Number: PD 23 1417 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Nanoscale Interactions Apply for PD 23 1179 Funding Number: PD 23 1179 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Environmental Sustainability Apply for PD 23 7643 Funding Number: PD 23 7643 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CyberCorps(R) Scholarship for Service Apply for 23 574 Funding Number: 23 574 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Standards Coordination Office Curricula Development Cooperative Agreement Program (SCO CD CAP) Apply for 2023 NIST SCOCD 01 Funding Number: 2023 NIST SCOCD 01 Agency: Department of Commerce, National Institute of Standards and Technology Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Small Business Innovation Research (SBIR) Program Phase II Apply for 2023 NIST SBIR 02 Funding Number: 2023 NIST SBIR 02 Agency: Department of Commerce, National Institute of Standards and Technology Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Computer and Information Science and Engineering (CISE) Research Initiation Initiative Apply for 23 576 Funding Number: 23 576 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $175,000 |
| Modeling relationships of hydromorphology, nutrient dynamics, and algal production in backwaters of the Lower Mississippi River Apply for W81EWF 23 SOI 0005 Funding Number: W81EWF 23 SOI 0005 Agency: Department of Defense, Engineer Research and Development Center Category: Science and Technology and other Research and Development Funding Amount: $40,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HT9425 23 PCRP EIRA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.